Arena Pharmaceuticals
 
BELVIQ® (lorcaserin HCl)
BELVIQ is approved by the FDA and will be available only after DEA scheduling is effective. Investors click here for additional information.
BELVIQ Published in New England Journal of Medicine
The BELVIQ Phase 3 BLOOM trial was published in the New England Journal of Medicine.
Pipeline
Pipeline of novel and selective drug candidates.
Investors
Our vision is to be the recognized world leader in GPCR drug discovery and development.
Press Releases
More...

2013 Annual Meeting of Stockholders
Annual Report 2012 Annual Report (PDF)
2013 Proxy Statement (PDF)

If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. Arena is not responsible for the content of this linked page.
 

This page last updated 04/29/2013
Additional Information regarding Arena is available in its SEC filings
© Copyright 2000-2013 Arena Pharmaceuticals, Inc.
All Rights Reserverd
Terms and Conditions
Privacy Statement


ABOUT US PROGRAMS GPCR TECHNOLOGY INVESTORS CAREERS